EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline

Medicus Pharma Ltd. (NASDAQ:MDCX) on Wednesday said it will present new Phase 1 clinical data for its investigational therapy Teverelix at the American Association of Clinical Endocrinology Annual Meeting 2026. It will highlight early evidence supporting its long-acting profile and potential use across multiple indications. The company positions Teverelix, a next-generation GnRH antagonist, as a first-in-market product targeting cardiovascular high-risk advanced prostate cancer patients and those with acute urinary retention relapse (AURr) episodes due to enlarged prostate. The company said it collectively represents an approximately $6 billion market opportunity. The company is also developing Teverelix for hormone-driven conditions, with potential applications in women's health, including endometriosis and uterine fibroids. Medicus Pharma Phase 1 Data Highlights Estradiol Suppression The upcoming presentation will feature results from two Phase 1 studies, TEVERELIX HFV1 and HFV2, conducted in Germany. The trials enrolled 48 healthy premenopausal women and evaluated single-dose subcutaneous administration of Teverelix. Findings showed predictable and dose-dependent suppression of estradiol levels. Some participants reached levels within the clinically relevant Barbieri therapeutic window, suggesting a balance between efficacy and tolerability. Pharmacokinetics Support Long-Acting Potential The pharmacokinetic profile of Teverelix indicated characteristics consistent with a depot formulation. The therapy demonstrated rapid initial absorption within approximately 0.5 to 2 hours, followed by sustained exposure and a secondary peak between one and three weeks. The reported terminal half-life ranged from about 14 to 23 days, supporting the potential for infrequent dosing strategies. Safety And Bone Health Profile Remain Stable Bone turnover biomarkers, including DPD and NTx, remained within normal ranges with minimal variation through Day 29. The company also reported no unexpected safety signals across both studies, indicating an acceptable tolerability profile in early testing. Medicus Pharma Expansion Into Endometriosis Under Evaluation Medicus said the data provide a mechanistic and pharmacologic foundation for advancing Teverelix into patient-based studies. The company is exploring its use in symptomatic endometriosis, an estrogen-dependent condition. The company is planning the development program in collaboration with Omics Labs in the United Arab Emirates, incorporating a genomics-enabled strategy. This approach may include hormonal pathway profiling, biomarker-based patient selection, and precision-informed clinical trial design. Currently, no long-acting injectable GnRH antagonists have approval for endometriosis, which positions Teverelix as a potential entrant in this segment if further studies validate its efficacy and safety. MDCX Stock Price Activity: Medicus Pharma shares were up 9.45% at $0.44 during premarket trading on xxxday, according to Benzinga Pro data. Image via Shutterstock